Carcinotech is focused on treating cancers and is based at the Roslin Innovation Centre on the outskirts of Edinburgh.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Dyneval specializes in portable technology for cattle semen analysis, focusing on the precise measurement of semen quality. Its innovative technology assesses semen motility under quasi-in-vivo conditions, providing valuable insights into spermatozoa behavior. By utilizing dynescan data, Dyneval aids in informing breeding plans and confirming semen quality throughout the supply chain. This approach not only enhances livestock production but also contributes to improved food security and reduced methane emissions, allowing farmers to address issues related to poor conception rates effectively.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
RAB Microfluidics specializes in developing innovative lab-on-a-chip technology aimed at transforming oil analysis processes. By utilizing patented microfluidic technology, the company offers real-time diagnostics for lubricated machinery, enabling early detection of potential failures and preventing costly equipment breakdowns. This dynamic approach provides clients with laboratory-quality data and actionable insights for effective asset condition management, significantly reducing costs compared to traditional methods. Founded on a decade of research from the University of Aberdeen, RAB Microfluidics is recognized as a pioneer in microfluidic technology for oil applications in Europe. With a dedicated advisory team boasting over 60 years of expertise, the company is committed to addressing the needs of diverse industries, including oil and gas, aerospace, and power generation, by making oil testing mobile, rapid, and routine.
Particle Analytics Ltd. is a software company based in Edinburgh, United Kingdom, that specializes in technologies for the preparation, visualization, and analysis of simulation data related to particles and industrial bulk solids. Established in March 2015 as a spin-out from the University of Edinburgh, the company has quickly positioned itself as a disruptive force in its sector. Its software offers advanced post-processing capabilities that utilize temporal and spatial averaging techniques, enabling users to project and analyze particle information effectively. Additionally, the pre-processing tools allow for the creation and modification of geometries and meshes prior to simulation. By delivering significant efficiencies and improvements, Particle Analytics serves multinational organizations that manage large volumes of particulate solids, offering a substantial enhancement over existing solutions in the market.
Manus Neurodynamica Ltd manufactures medical diagnostic technologies for neuromotor impairments, including the non-invasive diagnosis and monitoring of Parkinson’s disease. Its technologies are used in academic research, pharmaceutical research, and non-medical applications. The company was founded in 2008 and is based in North Shields, United Kingdom.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Censo Biotechnologies Ltd engages in the development of stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. Its induced pluripotent stem cells (iPSCs) technology enables creation of stem cells in the laboratory from any person who donates a skin or blood sample. The company provides services, such as human tissue sample procurement, iPSC generation, iPSC genome editing, differentiated cell protocol development and industrialization, production of differentiated cells of specific lineages, cell based assay development, and compound screening. Censo Biotechnologies Ltd was formerly known as Roslin Cellab Limited and changed its name to Censo Biotechnologies Ltd in May 2016. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in Cambridge, United Kingdom.
Censo Biotechnologies Ltd engages in the development of stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. Its induced pluripotent stem cells (iPSCs) technology enables creation of stem cells in the laboratory from any person who donates a skin or blood sample. The company provides services, such as human tissue sample procurement, iPSC generation, iPSC genome editing, differentiated cell protocol development and industrialization, production of differentiated cells of specific lineages, cell based assay development, and compound screening. Censo Biotechnologies Ltd was formerly known as Roslin Cellab Limited and changed its name to Censo Biotechnologies Ltd in May 2016. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in Cambridge, United Kingdom.
Wobble Genomics is a biotechnology firm focused on enhancing the efficiency of RNA and DNA sequencing to facilitate the discovery and detection of nucleic acid biomarkers. The company employs a blend of biochemistry and bioinformatics to achieve unprecedented sensitivity and accuracy in identifying novel biomarkers. By optimizing sampling efficiency during sequencing, Wobble Genomics aims to reduce costs for medical researchers, thereby advancing the field of genomic analysis and improving diagnostic capabilities.
Novosound Ltd, founded in 2016 and based in Edinburgh, United Kingdom, specializes in the design and manufacture of innovative ultrasound sensors aimed at various sectors, including aerospace, oil and gas, industrial, medical, veterinary, and dental. As the first spin-out from the University of the West of Scotland, the company employs advanced thin-film manufacturing techniques to overcome the limitations associated with traditional ultrasound technology. Novosound develops highly customizable and scalable solutions, producing sensors, systems, and software that facilitate high-resolution imaging for non-destructive testing and medical applications. The company's focus on cutting-edge technology positions it as a leader in the field of ultrasound imaging and measurement.
Particle Analytics Ltd. is a software company based in Edinburgh, United Kingdom, that specializes in technologies for the preparation, visualization, and analysis of simulation data related to particles and industrial bulk solids. Established in March 2015 as a spin-out from the University of Edinburgh, the company has quickly positioned itself as a disruptive force in its sector. Its software offers advanced post-processing capabilities that utilize temporal and spatial averaging techniques, enabling users to project and analyze particle information effectively. Additionally, the pre-processing tools allow for the creation and modification of geometries and meshes prior to simulation. By delivering significant efficiencies and improvements, Particle Analytics serves multinational organizations that manage large volumes of particulate solids, offering a substantial enhancement over existing solutions in the market.
CuanTec Ltd is a Scottish biotechnology company based in Motherwell, specializing in the production of biodegradable plastic films for the food industry. Founded in 2016, CuanTec utilizes a sustainable approach by extracting chitin from waste generated by the fisheries sector, particularly from langoustines sourced from the pollution-free waters of the North Atlantic. This extraction is achieved through a low-energy fermentation process that employs harmless bacteria, resulting in a high-quality product with minimal waste. The company’s compostable and antimicrobial bioplastics serve as an environmentally friendly alternative to conventional packaging, aiming to reduce plastic pollution and food waste while extending the shelf life of fresh food. By employing a circular economy model, CuanTec effectively transforms marine waste into valuable packaging solutions.
Censo Biotechnologies Ltd engages in the development of stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. Its induced pluripotent stem cells (iPSCs) technology enables creation of stem cells in the laboratory from any person who donates a skin or blood sample. The company provides services, such as human tissue sample procurement, iPSC generation, iPSC genome editing, differentiated cell protocol development and industrialization, production of differentiated cells of specific lineages, cell based assay development, and compound screening. Censo Biotechnologies Ltd was formerly known as Roslin Cellab Limited and changed its name to Censo Biotechnologies Ltd in May 2016. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in Cambridge, United Kingdom.
Novosound Ltd, founded in 2016 and based in Edinburgh, United Kingdom, specializes in the design and manufacture of innovative ultrasound sensors aimed at various sectors, including aerospace, oil and gas, industrial, medical, veterinary, and dental. As the first spin-out from the University of the West of Scotland, the company employs advanced thin-film manufacturing techniques to overcome the limitations associated with traditional ultrasound technology. Novosound develops highly customizable and scalable solutions, producing sensors, systems, and software that facilitate high-resolution imaging for non-destructive testing and medical applications. The company's focus on cutting-edge technology positions it as a leader in the field of ultrasound imaging and measurement.
Novosound Ltd, founded in 2016 and based in Edinburgh, United Kingdom, specializes in the design and manufacture of innovative ultrasound sensors aimed at various sectors, including aerospace, oil and gas, industrial, medical, veterinary, and dental. As the first spin-out from the University of the West of Scotland, the company employs advanced thin-film manufacturing techniques to overcome the limitations associated with traditional ultrasound technology. Novosound develops highly customizable and scalable solutions, producing sensors, systems, and software that facilitate high-resolution imaging for non-destructive testing and medical applications. The company's focus on cutting-edge technology positions it as a leader in the field of ultrasound imaging and measurement.
Kenoteq is a clean tech company that specializes in the production of an innovative unfired eco-brick made from 90% recycled content sourced from demolition and construction waste. This product stands out due to its environmentally friendly manufacturing process, which eliminates the need for energy-intensive gas usage and avoids the use of cement, common in traditional clay-fired bricks. By focusing on low resource consumption and sustainable practices, Kenoteq aims to provide clients with a recyclable building material that significantly reduces life cycle environmental impacts.
Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.
MOFgen Ltd is an award winning VC-backed SME spin-out from the University of St Andrews and is the first company to commercialise MOFs for medical and therapeutic applications. The company’s patented technology was pioneered in the laboratories of world renowned porous material scientist Prof Russell Morris FRS within the School of Chemistry at St Andrews. With roots in the leading research group of its field, MOFgen is exploiting its strong IP and knowhow assets in the areas of MOF design, application, manufacturing and formulation to deliver cutting edge solutions to healthcare challenges. Through an ethos of innovation and collaboration, MOFgen works closely with its partners, to develop bespoke solutions to prevent healthcare associated infections, avoid bacterial resistance, heal chronic wounds and address arterial access.
CuanTec Ltd is a Scottish biotechnology company based in Motherwell, specializing in the production of biodegradable plastic films for the food industry. Founded in 2016, CuanTec utilizes a sustainable approach by extracting chitin from waste generated by the fisheries sector, particularly from langoustines sourced from the pollution-free waters of the North Atlantic. This extraction is achieved through a low-energy fermentation process that employs harmless bacteria, resulting in a high-quality product with minimal waste. The company’s compostable and antimicrobial bioplastics serve as an environmentally friendly alternative to conventional packaging, aiming to reduce plastic pollution and food waste while extending the shelf life of fresh food. By employing a circular economy model, CuanTec effectively transforms marine waste into valuable packaging solutions.
Mironid Limited is a drug discovery company focused on developing therapeutic candidates aimed at treating degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014 and based in Newhouse, United Kingdom, Mironid employs a unique Physiology Mirroring Approach to design assays that replicate the drug target's conformation and environment found in living cells. The company's pipeline features Novel ShoLo compounds for chronic inflammatory diseases and Novel LoAc compounds for degenerative kidney diseases. By modulating the activity of key cell signaling proteins, Mironid aims to create high-value therapeutics that address significant unmet medical needs, thereby enhancing the health and quality of life for patients.
CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in manufacturing biobased materials derived from waste streams of the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms, and is used in various applications, including paints and coatings, paper, food, personal care, home care, cosmetics, concrete, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on sustainable resources, aiming to provide innovative solutions that reduce reliance on hydrocarbon feedstocks while offering cost-effective products for its clients.
Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, focused on developing innovative self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010 and formerly known as RRG Coatings Ltd., the company specializes in a range of applications, including spine, trauma, and extremities, as well as biologics. Taragenyx's product line features therapeutic implants, surface-active coatings, and skeletal implants designed to address surgical complications associated with infection, pain, and thrombosis. By integrating active pharmaceuticals and biologics into the implant coatings, Taragenyx aims to facilitate accelerated bone growth, promote faster healing, and minimize the risk of postoperative complications.
Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, specializing in the design and supply of tuneable peptide hydrogels for various applications in cell culture research. Established in 2012, the company focuses on providing hydrogels that closely mimic the chemical and physical properties of natural tissues, enabling researchers to grow, proliferate, and manipulate cells within realistic 3D environments. Their products are utilized in fundamental cell research, toxicology and drug development, as well as cancer cell research, and aim to replace animal testing methods. Biogelx's patented hydrogel systems are marketed globally, offering academic institutions, medical researchers, and pharmaceutical companies a competitive alternative to existing 3D cell culture solutions. Additionally, these hydrogels hold potential for future applications in cell therapy and regenerative medicine.
Anacail Limited develops a technology for the generation of ozone inside sealed packages to oxidize surface contaminants and kill microorganisms. It develops an in-pack ozone system, which includes an ozone head that is connected to the face of the pack; and energized to produce intense electric fields that penetrate the pack to generate plasma and create ozone within the sealed package. The company also develops equipment that is installed onto a food processing line to generate sterilizing ozone inside sealed packaging; and devices for medical sterilization. Anacail Limited was incorporated in 2010 and is based in Glasgow, United Kingdom.
DestiNA Genomics Ltd. is a molecular diagnostic company based in Edinburgh, United Kingdom, specializing in the detection of nucleic acids and single nucleotide polymorphisms (SNPs). Founded in 2010 as a spin-out from the University of Edinburgh, the company has developed a unique, chemical-based system that is distinct from traditional enzymatic methods. DestiNA offers a range of reagents and probes for the detection of nucleic acids and mutations, as well as assay sets for drug profiling and development. Its technology is particularly effective for direct detection of micro-RNAs and is being integrated into various detection platforms, including colorimetric, fluorescent, and electrochemical systems. DestiNA Genomics has also established a subsidiary in Spain, DestiNA Genomica SL, to exploit its technologies in collaboration with local partners. The Spanish subsidiary has received funding from the Technological Fund of Invest in Spain to support its research and development initiatives.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2014. The company specializes in optical molecular imaging technology that facilitates image-guided therapy for the detection, diagnosis, and monitoring of diseases. It focuses on the discovery and development of small molecules and peptides that can be conjugated with fluorescent dyes, allowing for real-time disease detection during interventional procedures, such as surgery. Edinburgh Molecular Imaging has raised over £15 million in non-dilutive funding from organizations like the Wellcome Trust, EPSRC, and MRC to advance its innovative SMART Agents, which enhance molecular imaging capabilities. The team behind the company comprises experienced scientists and clinicians with extensive expertise in medicinal chemistry, biochemistry, cell biology, and clinical development, positioning the company to contribute significantly to the field of medical imaging.
CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in manufacturing biobased materials derived from waste streams of the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms, and is used in various applications, including paints and coatings, paper, food, personal care, home care, cosmetics, concrete, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on sustainable resources, aiming to provide innovative solutions that reduce reliance on hydrocarbon feedstocks while offering cost-effective products for its clients.
Insignia Technologies Ltd specializes in developing innovative smart pigments and inks that utilize sensing technologies for the food packaging industry. These pigments change color when exposed to gases or UV light, providing visual indicators of food freshness. The company's products include food freshness indicators and CO2 indicator pigments that alert users when food is past its best, thereby minimizing food wastage. Additionally, Insignia offers an embedded color-changing label that signals packaging damage for products stored in modified atmospheres, allowing for timely removal from the supply chain. The company is also expanding its offerings to include indicators for UV, oxygen, volatiles, and humidity, serving a variety of applications. Founded in 2008, Insignia Technologies is headquartered in Newhouse, United Kingdom.
Fixed Phage was founded with the aim of developing new products for various industries from our platform technology. Each of our core technologies is comprehensively described and protected by our IP portfolio. We work at our custom designed laboratory and support infrastructure facilities located at the prestigious West of Scotland Science Park. Our in-house abilities include all work required to identify, manufacture and work with bacteriophage. Fixed Phage continually invests in innovation and our team presents at conferences and exhibitions around the world. To learn about whether we will be presenting near you, please follow us on social media.
Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, focused on developing innovative self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010 and formerly known as RRG Coatings Ltd., the company specializes in a range of applications, including spine, trauma, and extremities, as well as biologics. Taragenyx's product line features therapeutic implants, surface-active coatings, and skeletal implants designed to address surgical complications associated with infection, pain, and thrombosis. By integrating active pharmaceuticals and biologics into the implant coatings, Taragenyx aims to facilitate accelerated bone growth, promote faster healing, and minimize the risk of postoperative complications.
Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.
Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, specializing in the design and supply of tuneable peptide hydrogels for various applications in cell culture research. Established in 2012, the company focuses on providing hydrogels that closely mimic the chemical and physical properties of natural tissues, enabling researchers to grow, proliferate, and manipulate cells within realistic 3D environments. Their products are utilized in fundamental cell research, toxicology and drug development, as well as cancer cell research, and aim to replace animal testing methods. Biogelx's patented hydrogel systems are marketed globally, offering academic institutions, medical researchers, and pharmaceutical companies a competitive alternative to existing 3D cell culture solutions. Additionally, these hydrogels hold potential for future applications in cell therapy and regenerative medicine.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.
Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.
Nandi Proteins Limited is a technology-driven company based in Edinburgh, United Kingdom, focused on enhancing the functional properties of proteins in food manufacturing and nutrition. Established in 2000 and spun out of Heriot Watt University in 2001, the company specializes in patented processes that improve common proteins such as whey, egg, and soy. Nandi Proteins aims to be a leader in denatured protein technology, facilitating growth through direct trading of value-added proteins and strategic licensing agreements with industry partners. Its innovative approach employs a combination of heat, time, and temperature control to modify proteins, enabling food and beverage manufacturers to achieve desirable characteristics and health benefits while efficiently extracting valuable components like enzymes.
NiTech Solutions Ltd. is a company based in Edinburgh, United Kingdom, specializing in the design and provision of continuous oscillatory baffled reactors and tubular reactors for various applications, including crystallization, biodiesel production, hydrogenation, polymerization, and pharmaceutical active pharmaceutical ingredients. Founded in 2003, NiTech focuses on enhancing process efficiency in the chemical, pharmaceutical, biotechnology, waste management, and food and drinks sectors. The company's innovative baffled reactor technology facilitates the mixing of liquid-liquid, liquid-solid, and gas-liquid-solid processes, enabling clients to transition from batch to continuous processes. This shift not only enhances operational efficiency but also reduces costs, energy consumption, and waste generation while improving product quality. NiTech's team comprises experts in process design, chemistry, and chemical engineering, ensuring the successful implementation of advanced and effective solutions for its clients.